In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
At PureCare Pharmacy, we actively support patients across Greater Houston and throughout Texas by assisting with prior authorizations, manufacturer copay programs, and personalized medication guidance
[10] Glutathione treated areas had significant improvement in other parameters as well
Monitoring focuses on glucose trends, kidney/liver context, lipids, and symptoms tied to reduced intake or GI effects
Shandong Eledeep Bio Tech Co., Ltd